CORT:NASDAQ
Corcept Therapeutics Inc
$113.98
arrow_upward
+2.11%(+2.36) 1D
$113.98
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 8, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CORT...
Open
$108.87
High
$115.28
Low
$108.25
Mkt. cap
12.32B
Avg. vol.
1.06M
Volume
1.05M
P/E ratio
267.53
52-wk high
$126.38
52-wk low
$28.66
EPS
$0.43
Beta
0.45
Shares outstanding
108.10M
No. of employees
730
Open
$108.87
High
$115.28
Low
$108.25
Mkt. cap
12.32B
Avg. vol.
1.06M
Volume
1.05M
P/E ratio
267.53
52-wk high
$126.38
52-wk low
$28.66
EPS
$0.43
Beta
0.45
Shares outstanding
108.10M
No. of employees
730
News stories
From web sources and news partners
Seeking Alpha
·
12 hours ago
Corcept: Not Cheap, But Backed By Real Structural Growth
Profile
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
About Corcept Therapeutics Inc
CEO-
Employees730
FoundedMay 13, 1998
HeadquartersMenlo Park, California, United States
SectorPharmaceutical industry
Websitecorcept.com